150 related articles for article (PubMed ID: 29073846)
21. Use of antilymphocyte induction therapy in liver transplantation.
Wall WJ
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
[TBL] [Abstract][Full Text] [Related]
22. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update.
Hertig A; Zuckermann A
Transpl Immunol; 2015 Jun; 32(3):179-87. PubMed ID: 25936966
[TBL] [Abstract][Full Text] [Related]
23. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
[TBL] [Abstract][Full Text] [Related]
24. [Melanoma in organ transplant patients].
Lévêque L; Dalac S; Dompmartin A; Louvet S; Euvrard S; Catteau B; Hazan M; Schollhamer M; Aubin F; Dreno B; Daguin P; Chevrant-Breton J; Frances C; Bismuth MJ; Tanter Y; Lambert D
Ann Dermatol Venereol; 2000 Feb; 127(2):160-5. PubMed ID: 10739973
[TBL] [Abstract][Full Text] [Related]
25. Malignancy With Immunosuppression After Renal Transplantation: A Competing Risk Analysis.
Yoshida T; Matsumura S; Imanaka T; Taniguchi A; Yamanaka K; Kishikawa H; Nishimura K
Transplant Proc; 2020; 52(6):1775-1777. PubMed ID: 32299709
[TBL] [Abstract][Full Text] [Related]
26. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
27. [Skin cancer in renal transplant recipients].
Mangino M; Schena FP
G Ital Nefrol; 2010; 27 Suppl 50():S75-80. PubMed ID: 20922700
[TBL] [Abstract][Full Text] [Related]
28. Post-renal transplant malignancies: Opportunities for prevention and early screening.
Turshudzhyan A
Cancer Treat Res Commun; 2021; 26():100283. PubMed ID: 33338850
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling for cardiac rejection surveillance is not predictive of post-transplantation skin cancer.
Hanlon A; O'Neill M; Fang F; Chen H; Lott J; Wigger M; Stasko T
Dermatol Surg; 2013 Oct; 39(10):1507-13. PubMed ID: 24090261
[TBL] [Abstract][Full Text] [Related]
30. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
31. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
32. Association of Pretransplant Skin Cancer With Posttransplant Malignancy, Graft Failure and Death in Kidney Transplant Recipients.
Kang W; Sampaio MS; Huang E; Bunnapradist S
Transplantation; 2017 Jun; 101(6):1303-1309. PubMed ID: 27336396
[TBL] [Abstract][Full Text] [Related]
33. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
[TBL] [Abstract][Full Text] [Related]
34. Acute rejection, T-cell-depleting antibodies, and cancer after transplantation.
Lim WH; Turner RM; Chapman JR; Ma MK; Webster AC; Craig JC; Wong G
Transplantation; 2014 Apr; 97(8):817-25. PubMed ID: 24521777
[TBL] [Abstract][Full Text] [Related]
35. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
[TBL] [Abstract][Full Text] [Related]
36. Influence of induction therapy on rejection and survival in heart transplantation.
Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
[TBL] [Abstract][Full Text] [Related]
37. Impact of Rabbit Antithymocyte Globulin Dose on Long-term Outcomes in Heart Transplant Patients.
Aliabadi AZ; Grömmer M; Dunkler D; Eskandary F; Salameh O; Gökler J; Hutschala D; Steinlechner B; Opfermann P; Laufer G; Zuckermann AO
Transplantation; 2016 Mar; 100(3):685-93. PubMed ID: 26457604
[TBL] [Abstract][Full Text] [Related]
38. Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study.
Fattouh K; Ducroux E; Decullier E; Kanitakis J; Morelon E; Boissonnat P; Sebbag L; Jullien D; Euvrard S
Transpl Int; 2017 Nov; 30(11):1172-1180. PubMed ID: 28700114
[TBL] [Abstract][Full Text] [Related]
39. Stepwise minimization of the immunosuppressive therapy in pediatric liver transplantation. A conceptual approach towards operational tolerance.
Reding R; Gras J; Bourdeaux C; Wieers G; Truong QD; Latinne D; Sokal E; Janssen M; Lerut J; Otte JB; de Ville de Goyet J
Acta Gastroenterol Belg; 2005; 68(3):320-2. PubMed ID: 16268418
[TBL] [Abstract][Full Text] [Related]
40. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
